NASDAQ:NXTC - NextCure Stock Price, Forecast & News

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure Inc (NASDAQ:NXTC) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. The company earned $1.58 million during the quarter, compared to the consensus estimate of $1.50 million. View NextCure's Earnings History.

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for NextCure.

6 Wall Street analysts have issued 1-year price objectives for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they anticipate NextCure's stock price to reach $66.17 in the next twelve months. This suggests a possible upside of 58.4% from the stock's current price. View Analyst Price Targets for NextCure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Media stories about NXTC stock have been trending very negative on Saturday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NextCure earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for NextCure.

NextCure saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 1,220,000 shares, an increase of 6.1% from the January 30th total of 1,150,000 shares. Based on an average daily trading volume, of 454,600 shares, the days-to-cover ratio is presently 2.7 days. Approximately 7.6% of the shares of the company are short sold. View NextCure's Current Options Chain.

Some companies that are related to NextCure include BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Evotec (EVTCY), Nektar Therapeutics (NKTR), Arrowhead Pharmaceuticals (ARWR), FibroGen (FGEN), PTC Therapeutics (PTCT), Zai Lab (ZLAB), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Alkermes (ALKS), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include CVS Health (CVS), Amgen (AMGN), Alibaba Group (BABA), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Cisco Systems (CSCO), Home Depot (HD), Procter & Gamble (PG) and NVIDIA (NVDA).

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure's stock is owned by many different of retail and institutional investors. Top institutional investors include Sofinnova Investments Inc. (11.74%), Canaan Partners X LLC (9.91%), Lord Abbett & CO. LLC (6.34%), Alliancebernstein L.P. (4.67%), ArrowMark Colorado Holdings LLC (3.35%) and State Street Corp (1.83%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, EAM Global Investors LLC, EAM Investors LLC, UBS Group AG, J. Goldman & Co LP and Bamco Inc. NY. View Insider Buying and Selling for NextCure.

NXTC stock was bought by a variety of institutional investors in the last quarter, including Canaan Partners X LLC, Lord Abbett & CO. LLC, ArrowMark Colorado Holdings LLC, Alliancebernstein L.P., State Street Corp, Marshall Wace North America L.P., Sofinnova Investments Inc. and FMR LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $41.76.

NextCure has a market capitalization of $950.21 million. View Additional Information About NextCure.

The official website for NextCure is http://www.nextcure.com/.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]